Recruiting
Phase 4

Purified Cortrophin Gel

Sponsor:

ANI Pharmaceuticals

Code:

NCT07938164

Conditions

Acute Gouty Arthritis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Purified Cortophin Gel, 40 U

Purified Cortophin Gel 80 U

Study Details

Brief summary:

The goal of this clinical trial is to learn if Purified Cortrophin Gel can help people with acute gouty arthritis when they are having a sudden flare-up. It will also monitor participants for any potential side effects while on this therapy. The main question it aims to answer is: is there a change in gout pain intensity after receiving Purified Cortrophin Gel.

Researchers will compare two different doses of Purified Cortrophin Gel.

Participants will:

  • Receive one injection of Purified Cortrophin Gel
  • Have 2 in-person visits to the site and 3 virtual/telephone visits
  • Complete daily surveys about their gout flare

Conditions

Acute Gouty Arthritis

Study ID

NCT07938164

Start date

Jan 28, 2026

Status verified date

Sep, 2026

Completion date

Nov 30, 2027

Anticipated

Primary completion date

Nov 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Main inclusion criteria:

1. Signed informed consent to participate in this study.
2. Male and female patients, aged 18-90 years.
3. Meeting the 2015 Gout classification criteria of the ACR/EULAR collaborative initiative.
4. Onset of current acute gout flare within 5 days prior to study entry
5. Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS).
6. History of ≥ 1 gout flares within the 12 months prior to study entry
7. The patient meets at least one of the following criteria for NSAIDs or colchicine treatment options:

1. Minimum of one episode of inadequate response to treatment.
2. The investigator deems that the patient is either contraindicated or inappropriate for treatment with NSAIDs or colchicine. Inappropriateness could be due to anticipated changes in patient status (i.e., such as worsening of comorbidities or use of concomitant medication).
8. Patients must be willing and capable of using, and have access to, an electronic device (e.g., cellphone or internet connected computer/tablet) to be able to complete surveys.

Main exclusion criteria:

1. Patients with active or known history of scleroderma, osteoporosis, active or recurrent bacterial, fungal or viral infections, or ocular herpes simplex.
2. Recent surgery (within 2 weeks prior to randomization or have an unhealed operation wound(s)).
3. Patients with active or known history of a peptic ulcer, uncontrolled congestive heart failure, uncontrolled hypertension, or uncontrolled diabetes type 1 or 2, as deemed by investigator.
4. Patients with sensitivity to proteins derived from porcine sources.
5. Patients with primary adrenocortical insufficiency or adrenocortical hyperfunction.
6. Active flare of rheumatoid arthritis, infectious/septic arthritis, or other acute inflammatory arthritis at baseline.
7. Polyarticular gouty arthritis flare currently active in more than 4 joints.
8. Patients who have taken an investigational drug within five times the half-life of that investigational drug has passed or within 30 days of randomization.
9. Previous inclusion in this study.
10. Patients currently receiving dialysis.
11. Uncontrolled clinically significant hematologic, CNS, hepatic, pulmonary, gastrointestinal, metabolic, or endocrine disease as deemed by the investigator.
12. Presence of any medical or psychological condition or laboratory result that might create risk to the patients (or interfere with the patient's ability to comply with the protocol requirements, or to complete the study) in the opinion of the investigator.
13. Prior or current treatment with any ACTH product.
14. Pregnant or nursing (lactating) women. Women of childbearing potential are required to be using an acceptable method of contraception.

1. Contraception must be used for the entire study and for at least 30 days after the last dose of study drug.
2. Acceptable methods of contraception are:

i. hormonal methods, such as birth control pills, patches, injections, vaginal rings, or implants ii. barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm) iii. intrauterine device (IUD) iv. abstinence (no sex)
15. Patients taking urate-lowering therapy have to be on a stable dose and regimen for ≥2 weeks before entering the study and remain on a stable dosage and regimen for at least 1 week after Purified Cortrophin® Gel.
16. Use of specified pain relief medications or biologics (including glucocorticoids, narcotics, paracetamol/acetaminophen, NSAIDs, colchicine, IL-blockers and tumor necrosis factor \[TNF\] inhibitors) within specified periods prior to randomization.
17. Vaccination within 30 days prior to study enrollment and during the study period.

Study Design

Enrollment

160 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: 40 U Purified Cortrophin Gel

active comparator: 80 U Purified Cortrophin Gel

Interventions

Purified Cortophin Gel, 40 U

One injection of Purified Cortrophin Gel, 40 U

Purified Cortophin Gel 80 U

One injection of Purified Cortrophin Gel, 80 U

Primary outcome measure

  • Change in gout pain intensity from baseline in the target joint following PCG administration. [ Time Frame: From baseline to Day 3 ]

Central Contacts and Locations

Locations

Mass General Hospital

Recruiting

Boston, Massachusetts, United States, 02114

Contacts

Principal Investigator:

Hyon K Choi, MD, DrPH

More Information

Sponsor

ANI Pharmaceuticals

Last update posted

Nov 16, 2026

Last verified

Sep, 2026

Keywords

  • gout
  • gout flare
  • pcg
  • purified cortrophin gel

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by ANI Pharmaceuticals on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.